Navigation Links
Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology

were localized to the treatment site, with the most frequent being mild injection site pain.

Objective tumor responses, defined as 50% tumor shrinkage or complete disappearance, were observed in 12 of 39 (31%) of the lesions that were targeted for observation. Of these observed lesions, seven of 18 treated tumors (38%) and five of 21 untreated tumors (24%) showed objective responses. The response of untreated tumor lesions suggests the possibility of a systemic effect of the treatment. Two subjects showed activity in untreated tumors distant from the site of administration of the therapy, including one subject showing shrinkage and disappearance of lung tumors.

"This is the third set of interim clinical data to be released this year supporting the safety and tolerability of Inovio's electroporation technology for delivering DNA immunotherapeutics in humans. The objective tumor responses observed by Vical add to a body of data suggesting that electroporation of plasmid-based immunotherapeutics can induce immune and anti-tumor responses," said Dr. Avtar Dhillon, Inovio's President and CEO. "We look forward to advancing the business opportunities that become more apparent with such results."

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly enhance the potency of such immunotherapies.

Inovio's DNA-based immunotherapy products consist of DNA plasmids and the Elgen and MedPulser DNA delivery systems. DNA plasmids are designed to express antigens that can induce an immune response specific to a cancer or infectious disease-causing organism. These plasmids are created synthetically and readily manufacture
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
Post Your Comments:
(Date:12/22/2014)... Maine , Dec. 22, 2014  Mark ... analysis brief providing a summary of the 2015 ... plan enrollment trends.  According to ... for Planning and Evaluation, Department of Health and ... were enrolled in individual medical plans through the ...
(Date:12/22/2014)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, announced today that the first cohort ... and pharmacodynamic study with d-Methadone, the company,s N-methyl-D-aspartate ... Racemic methadone is a long-acting opioid used in ... therapy in opioid addiction.  It is constituted by ...
(Date:12/19/2014)... , December 19, 2014 ... services in the World announced the appointment of ... R. Vonsée, as Chief Channels and Partner Officer. ... since 2004 through to its acquisition by Oracle in ... Director at Geneva and subsequently ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4
... June 20, 2007 /PRNewswire-USNewswire/ -- Speaker,Nancy Pelosi issued ... veto of the stem cell bill: , "Once ... the American,people, of leading medical researchers, and of ... says 'no' to the hopes of,million of families ...
... June 20, 2007 /PRNewswire-USNewswire/ -- The,following is a transcript ... executive order: , East Room , 2:39 P.M. EDT ... is a,nation that leads the world in science and ... that could save lives and cure diseases. America is ...
Cached Medicine Technology:Remarks by President Bush on Stem Cell Veto and Executive Order 2Remarks by President Bush on Stem Cell Veto and Executive Order 3Remarks by President Bush on Stem Cell Veto and Executive Order 4Remarks by President Bush on Stem Cell Veto and Executive Order 5Remarks by President Bush on Stem Cell Veto and Executive Order 6
(Date:12/22/2014)... Only weeks following the announcement that Henderson, Nevada ... a battery manufacturer create 29 well-paying jobs in Mojave ... launching in Henderson to deliver yet another win ... sector is going to build a stronger middle class ... works with small businesses that rely on middle class ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
Breaking Medicine News(10 mins):Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... discovered an accomplice in breast cancer a master control ... reactions orchestrated by a cancer-causing gene (or oncogene) named Wnt1. ... back-to-back papers featured on the cover of the August 15 ... about the regulation of a Wnt oncogene," explains lead author ...
... By Jenifer Goodwin HealthDay Reporter , ... mistakes, admitting the error, saying "I,m sorry" and offering ... lawsuits, new research shows. In 2001, University ... workers to report medical mistakes. The program included a ...
... Supports (CLASS) Act a largely overlooked component of the ... potential to transform long-term care financing in the United States ... latest issue of Public Policy & Aging Report ... The SCAN Foundation , this installment of PPAR ...
... This release is available in French . ... boys with low parental monitoring are more likely to befriend ... to a new study published in the journal Addictive ... de Montral and Sainte-Justine University Hospital Research Center found that ...
... fellow Amy Speed-Andrews has examined how a specialized Iyengar yoga ... who have completed treatment, makes a difference in their recovery. ... to fill out a questionnaire about their physical and mental ... yoga and again at the end. After analyzing the data ...
... are developing the first device able to transmit American ... just completing its initial field test by participants in ... "This is the first study of how deaf people ... project leader Eve Riskin, a UW professor of electrical ...
Cached Medicine News:Health News:Researchers identify breast cancer culprits 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 3Health News:CLASS Act analysis reveals America's long-term care future 2Health News:Heavy drug-use among bad boys curbed by parental monitoring and peers 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3
... Delivery System (CDS) facilitates the ... the Aescula LV Left-Heart Lead. ... patented coronary sinus curve that ... access to the coronary sinus ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... provides quick, convenient, repetitive dispensing for ... have a polyethylene plunger and a ... use with most reagents. Application: ... separate volumes can be selected for ...
Medicine Products: